Skip Navigation LinksHome > February 15, 2002 - Volume 16 - Issue 3 > Cross-neutralizing antibodies against primary isolates in Af...
AIDS:
Correspondence

Cross-neutralizing antibodies against primary isolates in African women infected with HIV-1

Donners, Helen; Willems, Betty; Beirnaert, Els; Colebunders, Robert; Davis, David; van der Groen, Guido

Free Access
Article Outline
Collapse Box

Author Information

Laboratory of Virology, Department of Microbiology, Institute of Tropical Medicine, B-2000 Antwerp, Belgium.

Received: 18 September 2001; accepted: 24 September 2001.

In previous studies performed among patients seen at the HIV clinic, the Institute of Tropical Medicine, Antwerp, Belgium, a disproportionate number of African HIV-1-infected women were shown to have circulating antibodies that could neutralize different subtypes of primary HIV-1 isolates. However, some relevant factors were confounded because few Europeans were included in the first study [1], and most of the women in the second study were Africans [2]. The question is whether the disproportionate number of Africans occurs by chance or is a function of their sex or origin.

In this study, 168 plasma samples of African and European men and women (42 of each group) were screened in a randomized manner against primary CA4 (env subtype F), CA13 (env subtype H) from group M and VI686 from group O [1]. Sixteen plasma samples that cross-neutralized all three viruses were further tested against nine other primary isolates, belonging to group M (env A–H) and two of group O.

Neutralization indices (NI) were calculated for each plasma/isolate combination, i.e. the infectious virus titre, expressed in log10, in phytohaemagglutinin-stimulated peripheral blood mononuclear cell cultures divided by the titre after incubation in the presence of plasma. An NI greater than 1.0 (90% reduction) is taken as an indicator for neutralization.

The proportion of NI greater than 1.0 for each isolate tested was used in a binomial expansion to calculate the expected numbers of plasma samples that would neutralize none, one, two and three isolates. The expected values were compared with their observed values for each neutralization pattern and were then compared by χ2 analysis.

Sixteen out of 168 plasma samples (9.5%) neutralized the three isolates. Of these, 15 were Africans (P = 0.006) and one was European. Of the Africans, 10 were women (P = 0.009); the European was a woman.

From the 16 plasma samples that were able to neutralize the three isolates, only six of the African women, one African man and the European woman were able to neutralize 10 or 11 out of 11 of the wider range of isolates (P = 0.06; not statistically significant) (data not shown).

Although plasma from Africans showed a disproportionate number that could neutralize the three isolates, this phenomenom was also observed with the neutralization of one or two isolates (Table 1). The frequencies of neutralizing none, one, two or three isolates by plasma from Europeans showed a good fit with expected frequencies, indicating that the neutralization of one isolate did not influence the neutralization of the others. In contrast, for Africans there was a significant difference between expected and observed frequencies, and this is particularly evident in women.

Table 1
Table 1
Image Tools

Cross-neutralization is particularly apparent in the plasma of African women. When plasma were screened against three HIV-1 isolates, no African women had antibodies that were specific for the group O virus nor doubly specific group O and subtype H, although given the numbers of plasma samples that could neutralize these two isolates, seven or eight of the 42 plasma samples should have fallen into one of these two categories.

In contrast, 10 African women were able to neutralize all three isolates against an expected number of two or three. Although there was a similar trend among the African men, the distortion was not so evident because there were six plasma samples that were specific for either the subtype H or group O isolates, such that any difference from an assumed random distribution did not reach statistical significance (Table 1).

These observations are compatible with the idea that neutralization of the subtype H and group O isolates are not independent parameters in African women: the same set of antibodies may be able to neutralize both viruses. This resolves some of the anomalies obtained with previous results.

The disproportionate number of women with broad cross-neutralizing antibodies was probably a result of their being African, rather than because of their sex. In a previous study, we concluded that the neutralizing activity was antibody mediated [2]. Interestingly, Burrer et al. [3] also observed antibody-mediated neutralization, particularly in African women.

Our results show that there is a difference in neutralization patterns between African and European plasma, especially in African women. An attempt to generate human monoclonal antibodies from African women with broad cross-neutralizing capacity is ongoing.

Helen Donners

Betty Willems

Els Beirnaert

Robert Colebunders

David Davis

Guido van der Groen

Back to Top | Article Outline

References

1. Nyambi P, Nkengasong J, Lewi P. et al. Multivariate analysis of human immunodeficiency virus type 1 neutralisation data. J Virol 1996, 70: 6235–6243.

2. Beirnaert E, Nyambi P, Willems B. et al. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A–H) and group O primary HIV-1 isolates. J Med Virol 2000, 61: 14–24.

3. Burrer R, Salmon-Ceron D, Richert S. et al. Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients. J Virol 2001, 75: 5421–5424.

Cited By:

This article has been cited 11 time(s).

Plos One
Neutralizing Antibody Responses in Macaques Induced by Human Immunodeficiency Virus Type 1 Monovalent or Trivalent Envelope Glycoproteins
Quinnan, GV; Zhang, PF; Dong, M; Chen, H; Feng, YR; Lewis, M; Broder, CC
Plos One, 8(3): -.
ARTN e59803
CrossRef
Virology Journal
Neutralization sensitivity of HIV-1 subtype B' clinical isolates from former plasma donors in China
OuYang, YB; Sun, JP; Huang, Y; Lu, L; Xu, WS; Hu, XT; Hong, KX; Jiang, SB; Shao, YM; Ma, LY
Virology Journal, 10(): -.
ARTN 10
CrossRef
Journal of Medical Virology
Inter-subtype cross-neutralizing antibodies recognize epitopes on cell-associated HIV-1 virions
Donners, H; Davis, D; Willems, B; van der Groen, G
Journal of Medical Virology, 69(2): 173-181.
10.1002/jmv.10288
CrossRef
Journal of Virology
Dissecting the neutralizing antibody-specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors
Dhillon, AK; Donners, H; Pantophlet, R; Johnson, WE; Decker, JM; Shaw, GM; Lee, FH; Richman, DD; Doms, RW; Vanham, G; Burton, DR
Journal of Virology, 81(): 6548-6562.
10.1128/JVI.02749-06
CrossRef
Journal of Virology
A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120
Astronomo, RD; Lee, HK; Scanlan, CN; Pantophlet, R; Huang, CY; Wilson, IA; Blixt, O; Dwek, RA; Wong, CH; Burton, DR
Journal of Virology, 82(): 6359-6368.
10.1128/JVI.00293-08
CrossRef
Journal of Medical Virology
Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy
Cavacini, LA; Duval, M; Patil, A; Wood, C; Mayer, KH; Ruprecht, RM; Posner, MR
Journal of Medical Virology, 76(2): 146-152.
10.1002/jmv.20339
CrossRef
Vaccine
The first generation of candidate HIV-1 vaccines can induce antibodies able to neutralize primary isolates in assays with extended incubation phases
Donners, H; Vermoesen, T; Willems, B; Davis, D; van der Groen, G
Vaccine, 22(1): 104-111.
10.1016/S0264-410X(03)00530-9
CrossRef
Antiviral Research
Inhibition of replication of primary HIV-1 isolates in huPBL-NOD/Scid mice by antibodies from HIV-1 infected patients
Steyaert, S; Heyndrickx, L; Verhoye, L; Vermoesen, T; Donners, H; Fransen, K; Van Wanzeele, F; Vandergucht, B; Vanham, G; Leroux-Roels, G; Vanlandschoot, P
Antiviral Research, 75(2): 129-138.
10.1016/j.antiviral.2006.10.013
CrossRef
Journal of Virology
Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors
Gray, ES; Taylor, N; Wycuff, D; Moore, PL; Tomaras, GD; Wibmer, CK; Puren, A; DeCamp, A; Gilbert, PB; Wood, B; Montefiori, DC; Binley, JM; Shaw, GM; Haynes, BF; Mascola, JR; Morris, L
Journal of Virology, 83(): 8925-8937.
10.1128/JVI.00758-09
CrossRef
Journal of Virology
Broad Neutralization of Human Immunodeficiency Virus Type 1 Mediated by Plasma Antibodies against the gp41 Membrane Proximal External Region
Gray, ES; Madiga, MC; Moore, PL; Mlisana, K; Karim, SSA; Binley, JM; Shaw, GM; Mascola, JR; Morris, L
Journal of Virology, 83(): 11265-11274.
10.1128/JVI.01359-09
CrossRef
Virology
Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity
Cham, F; Zhang, PF; Heyndrickx, L; Bouma, P; Zhong, P; Katinger, H; Robinson, J; van der Groen, G; Quinnan, GV
Virology, 347(1): 36-51.
10.1016/j.virol.2005.11.019
CrossRef
Back to Top | Article Outline

© 2002 Lippincott Williams & Wilkins, Inc.

Login